ImmuCell Co. (NASDAQ:ICCC - Get Free Report) was the recipient of a large growth in short interest in the month of May. As of May 15th, there was short interest totalling 11,700 shares, a growth of 82.8% from the April 30th total of 6,400 shares. Approximately 0.2% of the company's shares are short sold. Based on an average trading volume of 23,800 shares, the short-interest ratio is currently 0.5 days.
Hedge Funds Weigh In On ImmuCell
Several large investors have recently modified their holdings of ICCC. Northern Trust Corp raised its stake in ImmuCell by 51.0% during the fourth quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company's stock worth $229,000 after acquiring an additional 14,982 shares during the period. Geode Capital Management LLC grew its holdings in shares of ImmuCell by 13.9% during the fourth quarter. Geode Capital Management LLC now owns 64,538 shares of the biotechnology company's stock valued at $332,000 after purchasing an additional 7,878 shares during the last quarter. Dauntless Investment Group LLC acquired a new stake in shares of ImmuCell during the 4th quarter worth approximately $676,000. Mesirow Financial Investment Management Inc. boosted its position in ImmuCell by 100.0% during the 4th quarter. Mesirow Financial Investment Management Inc. now owns 24,356 shares of the biotechnology company's stock valued at $125,000 after purchasing an additional 12,178 shares during the period. Finally, Citadel Advisors LLC acquired a new position in ImmuCell during the 4th quarter valued at about $149,000. Institutional investors own 13.47% of the company's stock.
ImmuCell Trading Down 1.7%
ICCC stock traded down $0.12 on Wednesday, hitting $6.75. 10,272 shares of the company were exchanged, compared to its average volume of 22,241. The stock has a market capitalization of $61.00 million, a price-to-earnings ratio of -13.50 and a beta of 0.23. The business's fifty day moving average is $5.53 and its two-hundred day moving average is $5.11. ImmuCell has a twelve month low of $3.34 and a twelve month high of $7.18. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.11 and a quick ratio of 1.44.
ImmuCell (NASDAQ:ICCC - Get Free Report) last issued its earnings results on Wednesday, May 14th. The biotechnology company reported $0.16 EPS for the quarter. The business had revenue of $8.07 million for the quarter. ImmuCell had a negative net margin of 15.99% and a negative return on equity of 15.32%.
ImmuCell Company Profile
(
Get Free Report)
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.
Featured Articles
Before you consider ImmuCell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuCell wasn't on the list.
While ImmuCell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
